Savara (SVRA) Competitors

Janux Therapeutics (NASDAQ:JANX) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking.

Does the MarketBeat Community prefer JANX or SVRA?

Savara received 257 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Janux Therapeutics an outperform vote while only 66.89% of users gave Savara an outperform vote.

Company	Underperform	Outperform
Janux Therapeutics	Outperform Votes 44 70.97%	Underperform Votes 18 29.03%
Savara	Outperform Votes 301 66.89%	Underperform Votes 149 33.11%

Which has higher earnings and valuation, JANX or SVRA?

Savara has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10.59M	162.58	-$58.29M	-$1.28	-22.75
Savara	N/A	N/A	-$54.70M	-$0.43	-6.73

Which has more volatility & risk, JANX or SVRA?

Janux Therapeutics has a beta of 3.23, suggesting that its stock price is 223% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Does the media favor JANX or SVRA?

In the previous week, Savara had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 13 mentions for Savara and 8 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.39 beat Savara's score of 0.36 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend JANX or SVRA?

Janux Therapeutics currently has a consensus target price of $92.44, suggesting a potential upside of 217.41%. Savara has a consensus target price of $8.83, suggesting a potential upside of 205.12%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Janux Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.08
Savara	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Do institutionals and insiders believe in JANX or SVRA?

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 29.4% of Janux Therapeutics shares are held by company insiders. Comparatively, 5.1% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is JANX or SVRA more profitable?

Savara has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	-463.91%	-10.47%	-9.86%
Savara	N/A	-58.89%	-46.44%

Summary

Janux Therapeutics beats Savara on 11 of the 18 factors compared between the two stocks.